Supplementary appendix: A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer

These are peer-reviewed supplementary materials for the article 'A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer' published in the Journal of Comparative Effectiveness Research.Additional Methodology: 3Figures: 5Tables: 7Inputs: 15Results: 19References: 31Introduction: In the absence of head-to-head trials comparing immunotherapies for advanced nonsquamous non-small-cell lung cancer (NsqNSCLC), a network meta-analysis (NMA) was conducted to compare the relative efficacy of these treatments. Materials & methods: A systematic literature review of randomized controlled trials evaluating first-line-to-progression and second-line treatments for advanced NsqNSCLC informed Bayesian NMAs for overall survival (OS) and progression-free survival (PFS) end points. Results: Among first-line-to-progression treatments, pembrolizumab + pemetrexed + platinum showed the greatest OS benefit versus other regimens and a PFS benefit versus all but three regimens. Among second-line treatments, an OS benefit was seen for atezolizumab, nivolumab and pembrolizumab versus docetaxel. Conclusion: Pembrolizumab + pemetrexed + platinum showed the maximum OS benefit in the first-line setting. In the second-line setting, anti-PD-1/anti-PD-L1 monotherapies were better than docetaxel.

本数据集为发表在《比较疗效研究杂志》上的文章《基于免疫治疗的晚期非鳞状非小细胞肺癌（NsqNSCLC）治疗的网络荟萃分析》的同行评审补充材料。附加方法：3个图表；5个表格；7个输入；19个结果；31个参考文献；引言：鉴于缺乏直接对比免疫治疗晚期非鳞状非小细胞肺癌（NsqNSCLC）的头对头试验，本研究进行了网络荟萃分析（NMA），以比较这些治疗的相对疗效。材料与方法：对评估晚期NsqNSCLC一线至疾病进展和二线治疗的随机对照试验的系统文献综述，为总生存期（OS）和无进展生存期（PFS）终点提供了贝叶斯网络荟萃分析。结果：在一线至疾病进展治疗中，与其它方案相比，帕博利珠单抗+培美曲塞+铂类药物显示出最大的OS益处，与除三种方案外的所有方案相比显示出PFS益处。在二线治疗中，阿替利珠单抗、尼伏单抗和帕博利珠单抗与多西他赛相比显示出OS益处。结论：帕博利珠单抗+培美曲塞+铂类药物在一线治疗中显示出最大的OS益处。在二线治疗中，抗PD-1/抗PD-L1单药治疗优于多西他赛。